346-360 of 463
The Harsh Truth Behind the Vaping Epidemic
Clinician's RoundtableThe Harsh Truth Behind the Vaping Epidemic
Paul Doghramji, MD
David H. Peyton, Ph.D.
What’s New in COPD Care: Updates to the GOLD Guidelines & Other Advances
Deep Breaths: Updates from CHESTWhat’s New in COPD Care: Updates to the GOLD Guidelines & Other Advances
Nicola A. Hanania, MD, MS, FCCP
Neil J. Freedman, MD
Singling Out Severe Asthma: New Breakthroughs in Treatment
Deep Breaths: Updates from CHESTSingling Out Severe Asthma: New Breakthroughs in Treatment
Sandhya Khurana, MD, FCCP
Monica Kraft, MD, FCCP
Catching Cystic Fibrosis: Key Diagnostic & Management Updates
Deep Breaths: Updates from CHESTCatching Cystic Fibrosis: Key Diagnostic & Management Updates
Kristina Montemayor, MD
Natalie E. West, MD
Allison Lambert, MD
Initiating the Right Interstitial Lung Disease Treatment Approach
Deep Breaths: Updates from CHESTInitiating the Right Interstitial Lung Disease Treatment Approach
Anoop Nambiar, MD
Joshua Mooney, MD, MS
Mario R. Nacinovich, Jr., MSc
Kalin Clifford, PharmD
- advertisement
The Real Cost of Smoking: Medical, Financial, and Societal Considerations
Primary Care TodayThe Real Cost of Smoking: Medical, Financial, and Societal Considerations
Brian P. McDonough, MD, FAAFP
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Drug Information UpdatesFDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
Rethinking Nicotine: The Campaign to Break the World's Tobacco Habit
Primary Care TodayRethinking Nicotine: The Campaign to Break the World's Tobacco Habit
Brian P. McDonough, MD, FAAFP
What is Idiopathic Pulmonary Fibrosis (IPF)?
Video LibraryWhat is Idiopathic Pulmonary Fibrosis (IPF)?
The Importance of Early Referral and Treatment for IPF
Video LibraryThe Importance of Early Referral and Treatment for IPF
- advertisement
Beyond the Data: E-cigarettes, an Emerging Public Health Challenge
Grand Rounds Nation®Beyond the Data: E-cigarettes, an Emerging Public Health Challenge
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Project Oncology®FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
Project Oncology®FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
